Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company is launching another round of layoffs in ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

Over the last three months, we've seen significantly more insider buying, than insider selling, at Bristol-Myers Squibb.

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...